Loading compound...
Tyrosine-protein kinase SYK inhibitor
Entospletinib (also known as Entospleti) is a small molecule drug currently being studied in clinical trials. It works by inhibiting a protein called tyrosine-protein kinase SYK. It is being investigated for various types of blood cancers, including certain leukemias and lymphomas.
How it worksEntospletinib works by blocking an enzyme called tyrosine-protein kinase SYK, which may help stop the growth of certain cancer cells.
Used for
Acute myeloid leukemiaFollicular lymphomaChronic lymphocytic leukemiaDiffuse large B-cell lymphomaMantle cell lymphoma
Conditions
acute myeloid leukemiafollicular lymphomachronic lymphocytic leukemiadiffuse large B-cell lymphomaMantle cell lymphoma
Class
SYK inhibitorSmall moleculeTyrosine-protein kinase SYK inhibitorHematologic
How to take
This drug is currently in the research and clinical trial phases (up to Phase 3) and is not yet widely available for general use.
Talk to your doctor
Questions to ask
- ·Is Entospletinib appropriate for my specific type of lymphoma?
- ·What phase of clinical trials is Entospletinib currently in?
- ·Are there known side effects for Entospletinib?
Educational summary derived from FDA labeling, AI-assisted. Not medical advice — consult a healthcare professional. Updated 2026-04-26.
